Theravance Biopharma, Inc.
NASDAQ:TBPH · NASDAQ Global Market
-$0.07 today
Vol 0.79M · Avg 0.43M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
35.7%
avg 42.9%
ROIC
-2.4%
avg -45.6%
ROA
21.8%
avg -20.8%
Analysis
ROE is currently the strongest return metric at 35.7% versus its period average of 42.9%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Rick E. Winningham | Chief Executive Officer & Director | $1.47M | — | 66 | $1.63M | 3.16% |
Aine Miller | Senior Vice President of Development & Head of Ireland Office | $747,322.00 | — | 49 | $177,334.00 | 0.34% |
Brett A. Grimaud | Senior Vice President, General Counsel & Secretary | $690,870.00 | — | 52 | $363,120.00 | 0.70% |
Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial & Medical Affairs | $682,942.00 | — | 61 | $232,457.00 | 0.45% |
Aziz Sawaf | Senior Vice President & Chief Financial Officer | $660,152.00 | — | 44 | $344,953.00 | 0.67% |
Stacy L. Pryce | Senior Vice President & Chief Strategy Officer | — | — | — | — | — |
Stuart Knight | Senior Vice President of IT&I and Chief Information Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
20
$3.82M
Net Sentiment
$3.82M
Net selling
Most Active
Farnum Rhonda
12 transactions
1–10 of 20
Analysis
Insiders reported 0 buys worth $0.00 and 20 sells worth $3.82M over the last 12 months. That adds up to net selling of $3.82M. Farnum Rhonda was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -31.3% | +5.9% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -31.3% over three years. Forward estimates point to Revenue at +5.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.67B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.53B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.48B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.19B
BlackRock Technology and Private Equity Term Trust
BTX
$1.08B
Replimune Group, Inc.
NASDAQ:REPL
$841.41M
Geron Corporation
NASDAQ:GERN
$821.15M
Valneva SE
NASDAQ:VALN
$507.30M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$184.05M
Who manages TBPH?
Theravance Biopharma, Inc. (TBPH) lists 7 active executives. The top listed executive is Rhonda F. Farnum, Chief Business Officer and Senior Vice President of Commercial & Medical Affairs.
Are TBPH insiders buying or selling?
Recent insider activity shows net buying of $2.44M.
Explore More
Continue the stock analysis
Jump to another research area for this company.